Loxo Oncology, Inc. Increase (Decrease) in Deferred Revenue
Loxo Oncology, Inc. reported Increase (Decrease) in Deferred Revenue of $228.70 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-03-01
- Loxo Oncology, Inc. increase (decrease) in deferred revenue for fiscal 2017 was $228.70M.
| Period end | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|
| 2017-12-31 | $228.70M 10-K · filed 2018-03-01 |